Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00380796 · ClinicalTrials.gov registry record

A Long-term Safety Study of Infliximab in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).

A clinical trial of COPD and Pulmonary Disease, Chronic Obstructive, sponsored by Centocor.

Completed
Registry status
88
Enrollment target
20
Study locations

NCT00380796 is a study of COPD and Pulmonary Disease, Chronic Obstructive that has completed, run by Centocor. The registered enrollment target is 88 participants, below the 2,417-participant average among 85 other COPD trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00380796, a study of COPD and Pulmonary Disease, Chronic Obstructive, has completed, sponsored by Centocor.

COMPLETED
Registry status
88 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this long-term observational study is designed to collect additional information on incidence of cancer and cause of death among patients who have participated in clinical trials of infliximab in the treatment of COPD. Patients must have received at least 1 dose of study agent (ie, placebo or infliximab) in the primary studies to be eligible for participation in this long-term follow-up study. Information on deaths and cancers will be collected twice yearly for a period of 5 years from each patient's last safety visit in the primary study.

Interventions

  • DRUG Collection of safety data for Cohort 1

Study Locations (20)

Pennsylvania

  • - Easton
  • - Hershey
  • - Philadelphia

California

  • - Anaheim
  • - San Diego

Florida

  • - Bay Pines
  • - Clearwater

Missouri

  • - Saint Charles
  • - St Louis

New York

  • - Endwell
  • - Larchmont

Georgia

  • - Blue Ridge

Maryland

  • - Baltimore

Massachusetts

  • - Springfield

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2006-04
Est. Completion 2009-12

Sponsor

Centocor

33 total trials

What the Registry Record Tells You About NCT00380796

The ClinicalTrials.gov registry entry for NCT00380796 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,417-participant average among 85 other COPD trials with a reported enrollment target (96% lower). The listed sponsor is Centocor, which has 33 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with COPD appearing as the primary indexed condition, and to 1 intervention - of which Collection of safety data for Cohort 1 is the first listed.

NCT00380796 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Pennsylvania, California, Florida.

Frequently Asked Questions

What is clinical trial NCT00380796 about?

NCT00380796 is a clinical study titled "A Long-term Safety Study of Infliximab in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).". The purpose of this long-term observational study is designed to collect additional information on incidence of cancer and cause of death among patients who have participated in clinical trials of infliximab in the treatment of COPD. Patients must have received at least 1 dose of study agent (ie, pl...

What is the current status of trial NCT00380796?

This trial is currently completed. The enrollment target is 88 participants. The study started on 2006-04. Estimated completion is 2009-12.

What conditions does trial NCT00380796 study?

This clinical trial studies the following conditions: COPD, Pulmonary Disease, Chronic Obstructive.

What interventions are being tested in trial NCT00380796?

The interventions under investigation include: Collection of safety data for Cohort 1 (DRUG).

Who is sponsoring clinical trial NCT00380796?

This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00380796 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COPD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.